Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 7/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CCR1 | P32246 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15076611 | 0.94 | CYP3A4 (0.53) | ENPP2LPAR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15076740 | 0.85 | MAPT (0.52) | CCR1TP53LMNAMAPT | |
| SCHEMBL15076548 | 0.85 | LMNA (0.56) | TP53LMNAMAPTHSD11B1 | |
| SCHEMBL15277080 | 0.84 | ENPP2 (0.52) | ENPP2LPAR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15277001 | 0.84 | CYP3A4 (0.47) | ENPP2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15076735 | 0.81 | MAPT (0.53) | ENPP2CCR1TP53LMNAMAPT | |
| SCHEMBL15076549 | 0.81 | LMNA (0.57) | ENPP2LPAR1TP53LMNAMAPT | |
| SCHEMBL15076352 | 0.81 | LMNA (0.61) | TP53LMNAMAPT | |
| SCHEMBL15076751 | 0.80 | CYP3A4 (0.73) | ENPP2LPAR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15076811 | 0.80 | CYP3A4 (0.58) | ENPP2LPAR1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC | 2017-11-23 | — | — | US | disclosed |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | ENPP2 1342/4885LPAR1 1815/4885CYP3A4 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.